In the first week of October, FDA Commissioner Scott Gottlieb, MD, announced 2 new initiatives intended to make drugs more widely available: the first is designed to help developers of complex generics better navigate the approvals process, and the second aims to streamline access to investigational treatments for compassionate use.
In the first week of October, FDA Commissioner Scott Gottlieb, MD, announced 2 new initiatives intended to make drugs more widely available: the first is designed to help developers of complex generics better navigate the approvals process, and the second aims to streamline access to investigational treatments for compassionate use.
On Monday, Gottlieb announced that the FDA has adopted a new set of policies to speed the approval of complex generic drugs, including injectable drugs, that are harder to produce as generics. Because development of complex generics poses additional challenges, innovator drugs face little competition even after losing patent protection. According to Gottlieb, “because brand-name versions of complex drug products are often higher-priced than many other brand name drugs, any steps we can take to encourage the development of generic competitors to complex drugs will have an outsized impact on access, and prices.”
In order to help reduce the number of review cycles necessary to approve these complex generics, the FDA has released new draft guidance, “Formal Meetings Between FDA and ANDA [abbreviated new drug application] Applicants of Complex Products Under GDUFA [Generic Drug User Fee Amendments],” that seeks to improve development timelines through earlier, better meetings between developers and the agency. The document describes the pathway for communication between the FDA and an applicant submitting an ANDA for a complex product, which the FDA defines as one with complex:
The guidance also describes in detail the purpose, scope, and criteria for holding product development, presubmission, and mid-cycle reviews between the applicant and the agency.
The second initiative, announced on Tuesday, aims to expand patient access to investigational treatments for compassionate use. Gottlieb wrote in his blog that the “FDA recognizes that time is critical for these seriously ill patients who do not have alternative therapies, and who cannot take part in a clinical trial of an investigational therapy,” and announced that the agency is revising a policy that had the potential to slow patient access to investigational drugs. Previously, a physician seeking to prescribe such a treatment to a patient under expanded access would require approval from the full Institutional Review Board (IRB) at his or her facility, and infrequent convening of such boards could potentially cause delays. Moving forward, approval from just 1 IRB member, such as a chairperson, will be required.
Gottlieb pointed out, however, that drug makers cannot be compelled to provide investigational drugs, and that some companies are concerned about how adverse events (AEs) that occur in patients who receive investigational drugs could be viewed by the FDA. In attempting to address some of these concerns, the agency updated its guidance document “Expanded Access to Investigational Drugs for Treatment Use—Questions and Answers.” In the guidance, the agency states that it is “not aware of instances in which [AE] information from expanded access has prevented FDA from approving a drug,” and said that its reviewers were aware that expanded access occurs outside a controlled trial setting, and that patients receiving expanded access may be experiencing more advanced stages of disease, may have comorbidities, or may be receiving additional therapies. It also clarifies the fact that AEs must be reported only if there is evidence that they were caused by the drug therapy.
Gottlieb also noted that the agency would continue to make simplifications and clarifications to its processes for expanded access in the days ahead.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.